MCID: MYX013
MIFTS: 45

Myxofibrosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Myxofibrosarcoma

MalaCards integrated aliases for Myxofibrosarcoma:

Name: Myxofibrosarcoma 12 58 15
Fibromyxosarcoma 58 71
Dermatofibrosarcoma Protuberans, Myxoid 71
Myxoid Malignant Fibrous Histiocytoma 58
Fibromyxoid Sarcoma 12

Characteristics:

Orphanet epidemiological data:

58
myxofibrosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0080534
NCIt 49 C6496
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C3714524
Orphanet 58 ORPHA79105
UMLS 71 C0334454 C3714524

Summaries for Myxofibrosarcoma

Disease Ontology : 12 A sarcoma that arises from the soft tissue and is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.

MalaCards based summary : Myxofibrosarcoma, also known as fibromyxosarcoma, is related to soft tissue sarcoma and fibrosarcoma. An important gene associated with Myxofibrosarcoma is CREB3L2 (CAMP Responsive Element Binding Protein 3 Like 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Sorafenib and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and heart, and related phenotypes are cellular and hematopoietic system

Wikipedia : 74 A histiocytoma is a tumour consisting of histiocytes. Histiocytes are cells that are a part of the... more...

Related Diseases for Myxofibrosarcoma

Diseases related to Myxofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 soft tissue sarcoma 31.7 TP53 MDM2 EWSR1
2 fibrosarcoma 31.2 TP53 THBS1 EWSR1 CREB3L1
3 spindle cell sarcoma 31.2 SERPINA3 MUC1 MDM2 CD34
4 malignant fibrous histiocytoma 31.1 TP53 SERPINA3 MUC1 MTAP MDM2 FUS
5 liposarcoma 31.0 TP53 MDM2 FUS EWSR1 CD34
6 ring chromosome 31.0 TP53 MDM2 EWSR1 CREB3L2
7 fibrous histiocytoma 31.0 TP53 SERPINA3 MTAP FUS EWSR1 CD34
8 sclerosing liposarcoma 31.0 MDM2 FUS CD34
9 retroperitoneal sarcoma 30.9 MDM2 EWSR1 CD34
10 leiomyosarcoma 30.9 TP53 SERPINA3 MUC1 MDM2
11 hemangiopericytoma, malignant 30.9 SERPINA3 MUC1 MDM2 CD34
12 dermatofibrosarcoma protuberans 30.9 TP53 SERPINA3 MDM2 CD34
13 mesenchymal cell neoplasm 30.8 TP53 SERPINA3 EWSR1 CD34
14 myoepithelial carcinoma 30.8 TP53 MUC1 EWSR1
15 myxoid chondrosarcoma 30.8 MUC1 MTAP EWSR1
16 myxoid liposarcoma 30.8 TP53 MDM2 FUS EWSR1 CREB3L2
17 neurilemmoma 30.8 SERPINA3 MUC1 CD34
18 gastrointestinal stromal tumor 30.8 TP53 KRAS CD44 CD34 CCNA2
19 heart sarcoma 30.7 MDM2 CD34
20 embryonal sarcoma 30.7 TP53 SERPINA3 MDM2
21 colorectal adenocarcinoma 30.6 TP53 MUC1 MDM2 KRAS CD44
22 adenocarcinoma 30.6 TP53 MUC4 MUC1 MDM2 KRAS CCNA2
23 connective tissue benign neoplasm 30.6 TP53 SERPINA3 MDM2 EWSR1 CD34
24 pleomorphic lipoma 30.6 SERPINA3 MDM2 CD34
25 pleomorphic adenoma 30.6 TP53 MUC1 MDM2
26 hemangioma 30.6 TP53 MUC1 KRAS CD34
27 malignant peripheral nerve sheath tumor 30.5 TP53 MUC1 MDM2 CD44 CD34
28 fibroma 30.5 SERPINA3 KRAS CD34
29 neurofibroma 30.5 TP53 MUC1 CD34
30 chondrosarcoma 30.5 SERPINA3 MUC1 MTAP MDM2 EWSR1
31 neuroblastoma 30.5 TP53 SKP2 MDM2 EWSR1 CD44 CCNA2
32 chordoma 30.5 TP53 SERPINA3 MUC1 MTAP
33 pleomorphic liposarcoma 30.5 SERPINA3 MUC1 MDM2 FUS EWSR1
34 cellular myxoid liposarcoma 30.4 SERPINA3 MDM2 FUS EWSR1
35 lymphangioma 30.4 TP53 SERPINA3 KRAS CD34
36 sarcoma 30.4 TP53 SERPINA3 MUC1 MTAP MDM2 KRAS
37 chondrosarcoma, extraskeletal myxoid 30.3 FUS EWSR1 CREB3L2 CD34
38 extraosseous osteosarcoma 30.2 MDM2 CD34
39 dedifferentiated liposarcoma 30.2 TP53 SERPINA3 MUC1 MDM2 FUS EWSR1
40 lipomatosis, multiple 30.1 SERPINA3 MDM2 FUS EWSR1 CD34
41 sarcoma, synovial 30.1 SERPINA3 MUC1 MDM2 FUS EWSR1 CD34
42 well-differentiated liposarcoma 30.1 TP53 SERPINA3 MUC1 MDM2 FUS EWSR1
43 leukemia, acute myeloid 29.8 TP53 SERPINA3 MDM2 KRAS EWSR1 CD44
44 ring chromosome 7 10.7 TP53 MDM2
45 splenic diffuse red pulp small b-cell lymphoma 10.7 TP53 CCNA2
46 actinic cheilitis 10.7 TP53 MDM2
47 hyperplastic polyposis syndrome 10.6 TP53 KRAS
48 esophagus verrucous carcinoma 10.6 TP53 MDM2
49 apocrine adenosis of breast 10.6 TP53 CCNA2
50 pancreatic foamy gland adenocarcinoma 10.6 TP53 MUC1

Graphical network of the top 20 diseases related to Myxofibrosarcoma:



Diseases related to Myxofibrosarcoma

Symptoms & Phenotypes for Myxofibrosarcoma

MGI Mouse Phenotypes related to Myxofibrosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ALDH1A1 CCNA2 CD34 CD44 CREB3L1 DCBLD2
2 hematopoietic system MP:0005397 10.11 CCNA2 CD34 CD44 CREB3L1 DCBLD2 DCN
3 endocrine/exocrine gland MP:0005379 10.06 ALDH1A1 CD109 CD44 DCN KRAS MDM2
4 immune system MP:0005387 10.06 CCNA2 CD109 CD34 CD44 DCN KRAS
5 integument MP:0010771 9.91 CD109 CD34 CD44 DCN KRAS MDM2
6 liver/biliary system MP:0005370 9.76 ALDH1A1 CD44 KRAS MDM2 MTAP SKP2
7 neoplasm MP:0002006 9.5 CD34 CD44 DCN KRAS MDM2 THBS1
8 respiratory system MP:0005388 9.23 ALDH1A1 CD44 DCBLD2 DCN KRAS MTAP

Drugs & Therapeutics for Myxofibrosarcoma

Drugs for Myxofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
2
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
3
Pembrolizumab Approved Phase 2 1374853-91-4
4
Dactinomycin Approved, Investigational Phase 2 50-76-0 457193 2019
5
Melphalan Approved Phase 2 148-82-3 460612 4053
6
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
7 Protein Kinase Inhibitors Phase 2
8 Angiogenesis Inhibitors Phase 2
9 Anesthetics Phase 2
10 Anti-Infective Agents Phase 2
11 Alkylating Agents Phase 2
12 Immunosuppressive Agents Phase 2
13 Anti-Bacterial Agents Phase 2
14 Antibiotics, Antitubercular Phase 2
15 Antineoplastic Agents, Immunological Phase 2
16 Immunoglobulins Phase 2
17 Antibodies Phase 2
18 Immunologic Factors Phase 2
19 Antibodies, Monoclonal Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
2 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
3 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
4 A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma Recruiting NCT04332874 Phase 2 Pembrolizumab;infusion of melphalan and dactinomycin
5 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab
6 A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Active, not recruiting NCT03474094 Phase 2
7 A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma Recruiting NCT04242238 Phase 1 DCC-3014;Avelumab
8 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Not yet recruiting NCT03967834

Search NIH Clinical Center for Myxofibrosarcoma

Genetic Tests for Myxofibrosarcoma

Anatomical Context for Myxofibrosarcoma

MalaCards organs/tissues related to Myxofibrosarcoma:

40
Bone, Breast, Heart, Lung, Brain, Skin, Prostate

Publications for Myxofibrosarcoma

Articles related to Myxofibrosarcoma:

(show top 50) (show all 521)
# Title Authors PMID Year
1
Retroperitoneal Myxofibrosarcoma: A Controversial Entity. 61
32345539 2020
2
Myxofibrosarcoma of the scalp with difficult preoperative diagnosis: A case report and review of the literature. 61
32548167 2020
3
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. 61
32161142 2020
4
Clinical relevance and functional significance of cell-free microRNA-1260b expression profiles in infiltrative myxofibrosarcoma. 61
32523124 2020
5
Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. 61
32127392 2020
6
Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway. 61
32559583 2020
7
SKP2 My Lou, My Darling. 61
32540853 2020
8
Complete remission of a case of high-grade myxofibrosarcoma with lung metastases after modified MAID regimen chemotherapy. 61
32427061 2020
9
Sarcoma metastasis to the pancreas: experience at a single institution. 61
32311873 2020
10
Proteomic research in sarcomas - current status and future opportunities. 61
31722230 2020
11
Myxofibrosarcoma of the mandible: a case report and review of the literature. 61
32299394 2020
12
The surgical management of sarcomas of the chest wall: A 13-year single institution experience. 61
32291186 2020
13
Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). 61
32138705 2020
14
5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study. 61
32138774 2020
15
Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma. 61
32076024 2020
16
Abdominal metastases of primary extremity soft tissue sarcoma: A systematic review. 61
32133276 2020
17
Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma. 61
31853575 2020
18
What is an adequate margin for infiltrative soft-tissue sarcomas? 61
31627932 2020
19
Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015. 61
31969161 2020
20
The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives. 61
32450554 2020
21
The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. 61
32277670 2020
22
Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma. 61
31742892 2020
23
Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review. 61
31651522 2020
24
Grading in Myxofibrosarcoma of the Extremities Can Predict Survival and Local Control. 61
32268331 2020
25
[A Case of Dedifferentiated Liposarcoma of the Spermatic Cord]. 61
31933339 2019
26
Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter. 61
31882696 2019
27
Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤ 40 years: a study of 116 patients. 61
31471922 2019
28
Primary low grade myxofibrosarcoma of the liver with benign presentation but malignant outcome: a case report. 61
31718576 2019
29
Coexistance of a well differentiated liposarcoma and dedifferentiated low grade myxofibrosarcoma of the scrotum. A rare case and review of the literature. 61
32007114 2019
30
Seven-year follow-up of spontaneous bone regeneration following segmental mandibulectomy: Alternative option for mandibular reconstruction. 61
31803391 2019
31
Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma. 61
31662543 2019
32
Upper extremity myxofibrosarcoma mimicking an erosive inflammatory arthritis: a case report. 61
30989248 2019
33
Does pre-operative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities? 61
31111597 2019
34
Small soft tissue masses indeterminate at imaging: histological diagnoses at a tertiary orthopedic oncology clinic. 61
30903259 2019
35
Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. 61
31624749 2019
36
Spindle cell liposarcoma with a TRIO-TERT fusion transcript. 61
30793229 2019
37
Thermal Imaging Facilitates Design of a Keystone Perforator Island Flap for a Myxofibrosarcoma Resection Reconstruction: Case Report. 61
31592380 2019
38
Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. 61
31331295 2019
39
Identification of infectious species after resection of soft-tissue sarcomas. 61
30816563 2019
40
Prognostic Factors and Outcomes for Patients With Myxofibrosarcoma: A 13-Year Retrospective Evaluation. 61
31177139 2019
41
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. 61
30962320 2019
42
CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. 61
30942427 2019
43
Spontaneous Regression of Myxofibrosarcoma of the Thigh after Open Biopsy. 61
31182952 2019
44
Surgical Reconstruction after Resection of a Large Myxofibrosarcoma of the Upper Extremity. 61
31363294 2019
45
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. 61
31096717 2019
46
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. 61
30547207 2019
47
Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. 61
31412008 2019
48
Aggressive invasive recurrence of a right atrial myxofibrosarcoma. 61
30851052 2019
49
Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. 61
30737712 2019
50
Malignant solitary fibrous tumor in the subcutis: Report of a rare superficial malignant type and review of published work. 61
30614065 2019

Variations for Myxofibrosarcoma

Copy number variations for Myxofibrosarcoma from CNVD:

7 (show all 47)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 29705 1 234600000 241700000 Loss AKT3 Myxofibrosarcoma
2 38875 10 105700000 114900000 Loss FACL5 Myxofibrosarcoma
3 39423 10 114900000 127400000 Loss DMBT1 Myxofibrosarcoma
4 42687 10 3800000 6700000 Loss DNMT2 Myxofibrosarcoma
5 47803 10 98000000 105700000 Loss HOX11 Myxofibrosarcoma
6 47805 10 98000000 105700000 Loss PLAU Myxofibrosarcoma
7 49687 11 110000000 120700000 Loss PIG8 Myxofibrosarcoma
8 51757 11 130300000 134452384 Loss ADAMTS8 Myxofibrosarcoma
9 54382 11 43400000 48800000 Loss KAI1 Myxofibrosarcoma
10 61474 12 1 14800000 Gain CCND2 Myxofibrosarcoma
11 61522 12 1 33200000 Loss LRP6 Myxofibrosarcoma
12 66186 12 26300000 33200000 Gain KRAG Myxofibrosarcoma
13 70913 12 66000000 69800000 Gain HMGIC Myxofibrosarcoma
14 73112 12 91200000 94800000 Loss BTG1 Myxofibrosarcoma
15 108897 17 23200000 35400000 Loss LIG3 Myxofibrosarcoma
16 115128 17 54900000 59900000 Gain TBX2 Myxofibrosarcoma
17 124176 19 1 6900000 Gain SH3GL1 Myxofibrosarcoma
18 143681 2 23900000 31900000 Loss ALK Myxofibrosarcoma
19 147727 2 69800000 136600000 Loss CXCR4 Myxofibrosarcoma
20 148303 2 75400000 83700000 Loss REG1A Myxofibrosarcoma
21 151117 20 17800000 27100000 Loss JAG1 Myxofibrosarcoma
22 170894 3 161200000 184200000 Loss MDS1 Myxofibrosarcoma
23 177567 3 58500000 63700000 Loss FHIT Myxofibrosarcoma
24 186568 4 36900000 114100000 Loss IBSP Myxofibrosarcoma
25 187541 4 50700000 52400000 Gain AFP Myxofibrosarcoma
26 208064 6 164400000 170899992 Loss PDCD2 Myxofibrosarcoma
27 217848 7 104755715 105039798 Amplificationlication SRPK2 Myxofibrosarcoma
28 217923 7 105888733 105925638 Amplificationlication PBEF1 Myxofibrosarcoma
29 218114 7 107788083 108096826 Amplificationlication NRCAM Myxofibrosarcoma
30 218692 7 116312458 116438439 Amplificationlication MET Myxofibrosarcoma
31 219052 7 121513158 121702088 Amplificationlication PTPRZ1 Myxofibrosarcoma
32 219257 7 124462440 124570037 Amplificationlication POT1 Myxofibrosarcoma
33 219480 7 127292201 127732658 Amplificationlication SND1 Myxofibrosarcoma
34 219953 7 132400000 147500000 Gain TIM1 Myxofibrosarcoma
35 223288 7 1855427 2272583 Amplificationlication MAD1L1 Myxofibrosarcoma
36 225548 7 47314752 47621742 Amplification TNS3 Myxofibrosarcoma
37 228044 7 73245192 73247014 Amplificationlication CLDN4 Myxofibrosarcoma
38 228772 7 81331444 81399452 Amplificationlication HGF Myxofibrosarcoma
39 229104 7 87257728 87461612 Amplificationlication RPIP9 Myxofibrosarcoma
40 229332 7 90095737 90839904 Amplificationlication PFTK1 Myxofibrosarcoma
41 229600 7 92234236 92465941 Amplificationlication CDK6 Myxofibrosarcoma
42 234953 8 140000000 146274826 Gain TG Myxofibrosarcoma
43 242385 8 7200000 43200000 Gain POLB Myxofibrosarcoma
44 262150 X 31500000 37500000 Gain OTC Myxofibrosarcoma
45 264432 X 65100000 67700000 Gain ED1 Myxofibrosarcoma
46 264546 X 67700000 72200000 Gain TED Myxofibrosarcoma
47 266520 X 98200000 110500000 Loss PLP Myxofibrosarcoma

Expression for Myxofibrosarcoma

Search GEO for disease gene expression data for Myxofibrosarcoma.

Pathways for Myxofibrosarcoma

Pathways related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TP53 THBS1 MDM2 KRAS CREB3L2 CREB3L1
2 12.73 TP53 SKP2 MDM2 KRAS CCNA2
3
Show member pathways
12.7 TP53 SKP2 MDM2 CD44 CCNA2
4
Show member pathways
12.7 TP53 MDM2 KRAS CREB3L2 CREB3L1 CCNA2
5
Show member pathways
12.44 TP53 SKP2 MDM2 CREB3L1 CCNA2
6 12.38 TP53 THBS1 MDM2 KRAS CD44
7 12.25 TP53 SKP2 MDM2 CCNA2
8 12.14 TP53 KRAS CREB3L2 CREB3L1 CCNA2
9
Show member pathways
12.09 TP53 MDM2 KRAS CREB3L2 CREB3L1
10 12.06 TP53 MDM2 KRAS CCNA2
11
Show member pathways
12.03 TP53 KRAS CREB3L2 CREB3L1
12
Show member pathways
12 THBS1 MUC4 MUC1 DCN
13 12 TP53 MDM2 FUS EWSR1 CCNA2
14 11.78 TP53 THBS1 MDM2 CD44
15 11.77 DCN CD44 CD34
16 11.74 TP53 THBS1 MDM2 KRAS DCN CD44
17 11.68 TP53 SKP2 MDM2 CCNA2
18
Show member pathways
11.62 TP53 MDM2 CCNA2
19 11.5 SKP2 MDM2 CCNA2
20 11.48 TP53 SKP2 MDM2 KRAS CREB3L2 CREB3L1
21 11.42 TP53 THBS1 MDM2 KRAS
22 11.38 TP53 MDM2 CCNA2
23 11.23 TP53 SKP2 MDM2 CCNA2

GO Terms for Myxofibrosarcoma

Biological processes related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 TP53 MDM2 KRAS CREB3L2 CD34
2 protein deubiquitination GO:0016579 9.81 TP53 SKP2 MDM2 CCNA2
3 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.61 THBS1 MDM2 CD44
4 Ras protein signal transduction GO:0007265 9.58 TP53 KRAS CCNA2
5 cardiac septum morphogenesis GO:0060411 9.54 TP53 MDM2
6 response to unfolded protein GO:0006986 9.54 THBS1 CREB3L2 CREB3L1
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 TP53 MUC1
8 response to magnesium ion GO:0032026 9.49 THBS1 MDM2
9 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.48 TP53 CREB3L1
10 positive regulation of transforming growth factor beta production GO:0071636 9.32 THBS1 CD34
11 cellular response to UV-C GO:0071494 9.26 TP53 MDM2
12 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.16 TP53 MUC1
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.13 TP53 MUC1 MDM2
14 cellular response to actinomycin D GO:0072717 8.62 TP53 MDM2

Molecular functions related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding GO:0035497 8.96 CREB3L2 CREB3L1
2 p53 binding GO:0002039 8.8 TP53 MUC1 MDM2

Sources for Myxofibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....